JP2007530068A5 - - Google Patents

Download PDF

Info

Publication number
JP2007530068A5
JP2007530068A5 JP2007505621A JP2007505621A JP2007530068A5 JP 2007530068 A5 JP2007530068 A5 JP 2007530068A5 JP 2007505621 A JP2007505621 A JP 2007505621A JP 2007505621 A JP2007505621 A JP 2007505621A JP 2007530068 A5 JP2007530068 A5 JP 2007530068A5
Authority
JP
Japan
Prior art keywords
antibody
seq
hosm
interaction
polynucleotide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2007505621A
Other languages
English (en)
Japanese (ja)
Other versions
JP4809828B2 (ja
JP2007530068A (ja
Filing date
Publication date
Priority claimed from GB0407197A external-priority patent/GB0407197D0/en
Priority claimed from GB0407193A external-priority patent/GB0407193D0/en
Application filed filed Critical
Priority claimed from PCT/GB2005/001147 external-priority patent/WO2005095457A2/en
Publication of JP2007530068A publication Critical patent/JP2007530068A/ja
Publication of JP2007530068A5 publication Critical patent/JP2007530068A5/ja
Application granted granted Critical
Publication of JP4809828B2 publication Critical patent/JP4809828B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2007505621A 2004-03-30 2005-03-29 免疫グロブリン Expired - Fee Related JP4809828B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0407197A GB0407197D0 (en) 2004-03-30 2004-03-30 Immunoglobulins
GB0407193.2 2004-03-30
GB0407193A GB0407193D0 (en) 2004-03-30 2004-03-30 Immunoglobulins
GB0407197.3 2004-03-30
PCT/GB2005/001147 WO2005095457A2 (en) 2004-03-30 2005-03-29 Immunoglobulins

Publications (3)

Publication Number Publication Date
JP2007530068A JP2007530068A (ja) 2007-11-01
JP2007530068A5 true JP2007530068A5 (https=) 2008-04-24
JP4809828B2 JP4809828B2 (ja) 2011-11-09

Family

ID=35064447

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007505621A Expired - Fee Related JP4809828B2 (ja) 2004-03-30 2005-03-29 免疫グロブリン

Country Status (24)

Country Link
US (2) US7858753B2 (https=)
EP (2) EP1730191B1 (https=)
JP (1) JP4809828B2 (https=)
KR (1) KR100942849B1 (https=)
AR (1) AR048516A1 (https=)
AT (1) ATE515515T1 (https=)
AU (1) AU2005229457B2 (https=)
BR (1) BRPI0509367A (https=)
CA (1) CA2562953A1 (https=)
CY (1) CY1112192T1 (https=)
DK (1) DK1730191T3 (https=)
HR (1) HRP20110657T1 (https=)
IL (1) IL178119A0 (https=)
MA (1) MA28541B1 (https=)
NO (1) NO20064886L (https=)
NZ (1) NZ550225A (https=)
PE (1) PE20060287A1 (https=)
PL (1) PL1730191T3 (https=)
PT (1) PT1730191E (https=)
RU (5) RU2429245C2 (https=)
SG (1) SG151292A1 (https=)
SI (1) SI1730191T1 (https=)
TW (1) TWI365746B (https=)
WO (1) WO2005095457A2 (https=)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
HRP20140240T4 (hr) 2005-11-30 2017-02-24 Abbvie Inc. Monoklonalna antitijela protiv amiloidnih beta proteina i njihova upotreba
US8691224B2 (en) 2005-11-30 2014-04-08 Abbvie Inc. Anti-Aβ globulomer 5F7 antibodies
WO2007098547A1 (en) * 2006-03-01 2007-09-07 Apollo Life Sciences Limited A molecule and chimeric molecules thereof
TWI422387B (zh) 2006-05-25 2014-01-11 Glaxo Group Ltd 免疫球蛋白
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
US8895004B2 (en) 2007-02-27 2014-11-25 AbbVie Deutschland GmbH & Co. KG Method for the treatment of amyloidoses
US10611835B2 (en) 2008-07-10 2020-04-07 Toray Industries, Inc. Pharmaceutical composition for treatment and prevention of cancer
BRPI0911926A2 (pt) 2008-08-05 2020-08-18 Toray Industries, Inc composições farmacêuticas, anticorpos e usos de um anticorpo ou um fragmento do mesmo.
WO2010027797A1 (en) * 2008-08-26 2010-03-11 Macrogenics Inc. T-cell receptor antibodies and methods of use thereof
US8309688B2 (en) * 2008-12-30 2012-11-13 Centocor Ortho Biotech Inc. Monkey homolog of human oncostatin M and methods of use thereof
EP2258723A1 (en) * 2009-06-02 2010-12-08 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Treatment of oncostatin M receptor ß mediated heart failure
US9115200B2 (en) 2010-02-04 2015-08-25 Toray Industries, Inc. Pharmaceutical composition for treating cancer using a monoclonal antibody having immunological reactivity with CAPRIN-1
RU2603742C2 (ru) 2010-02-04 2016-11-27 Торэй Индастриз, Инк. Фармацевтическая композиция для лечения и/или профилактики рака
DK2532680T3 (da) 2010-02-04 2015-07-20 Toray Industries Medicinsk sammensætning til behandling og/eller forebyggelse af cancer
CA2788545C (en) 2010-02-04 2019-03-26 Toray Industries, Inc. Pharmaceutical composition for treating and/or preventing cancer
DK2532366T3 (da) 2010-02-04 2017-01-02 Toray Industries Farmaceutisk sammensætning til behandling og/eller forebyggelse af cancer
US8987419B2 (en) 2010-04-15 2015-03-24 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
EP3533803B1 (en) 2010-08-14 2021-10-27 AbbVie Inc. Anti-amyloid-beta antibodies
KR101920250B1 (ko) * 2010-10-13 2018-11-20 얀센 바이오테크 인코포레이티드 인간 온코스타틴 m 항체 및 이용 방법
TWI504609B (zh) * 2010-11-23 2015-10-21 Glaxo Group Ltd 抗原結合蛋白質
RU2595400C2 (ru) 2011-08-04 2016-08-27 Торэй Индастриз, Инк. Фармацевтическая композиция для лечения и/или профилактики злокачественной опухоли
EP2740794B1 (en) 2011-08-04 2018-04-04 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prophylaxis of cancer
US9181348B2 (en) 2011-08-04 2015-11-10 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prophylaxis of cancer
BR112014021103A2 (pt) 2012-02-21 2019-10-15 Toray Industries, Inc Anticorpo, composição farmacêutica, droga de combinação, dna, método de tratamento e uso de anticorpo
US9260513B2 (en) 2012-02-21 2016-02-16 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of cancer
ES2739612T3 (es) 2012-02-21 2020-02-03 Toray Industries Composición farmacéutica para el tratamiento de cáncer
WO2013125654A1 (ja) 2012-02-21 2013-08-29 東レ株式会社 癌の治療及び/又は予防用医薬組成物
JP6107654B2 (ja) 2012-03-30 2017-04-05 東レ株式会社 肝臓癌の治療及び/又は予防用医薬組成物
WO2013147176A1 (ja) 2012-03-30 2013-10-03 東レ株式会社 胆嚢癌の治療及び/又は予防用医薬組成物
HUE056580T2 (hu) 2013-05-30 2022-02-28 Kiniksa Pharmaceuticals Ltd Onkosztatin-M-receptor antigénjét kötõ fehérjék
AU2014303375B2 (en) 2013-08-09 2019-07-04 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of cancer
US9550828B2 (en) 2013-09-05 2017-01-24 Boise State University Oncostatin M (OSM) antagonists for preventing cancer metastasis and IL-6 related disorders
US10519251B2 (en) 2013-12-30 2019-12-31 Epimab Biotherapeutics, Inc. Fabs-in-tandem immunoglobulin and uses thereof
PL3110434T3 (pl) * 2014-02-24 2019-01-31 Takeda Gmbh Białka fuzyjne uti
WO2016046738A1 (en) * 2014-09-24 2016-03-31 Università Degli Studi Di Padova Composition to induce bone marrow stem cell mobilization
AU2016211950A1 (en) * 2015-01-29 2017-07-13 Ares Trading S.A. Immunoassays for high positively charged proteins
US11421028B2 (en) 2016-02-06 2022-08-23 Epimab Biotherapeutics, Inc. Fabs-in-tandem immunoglobulin and uses thereof
MX2018011109A (es) 2016-03-28 2018-11-09 Toray Industries Composicion farmaceutica para el tratamiento y/o prevencion de cancer.
GB201614627D0 (en) * 2016-08-30 2016-10-12 Glaxosmithkline Ip Dev Ltd Antigen binding proteins
EP3788079A4 (en) 2018-05-03 2022-12-21 Shanghai Epimab Biotherapeutics Co., Ltd. ANTIBODIES WITH HIGH AFFINITY TO PD-1 AND LAG-3 AND BI-SPECIFIC BINDING PROTEINS PRODUCTION THEREOF
FR3090637A1 (fr) * 2018-12-21 2020-06-26 Universite De Poitiers Protéine de liaison spécifique capable de se lier spécifiquement à l’oncostatine M humaine (hOSM) et ses utilisations.
US11633457B2 (en) 2019-04-11 2023-04-25 Boise State University Pharmaceutical compositions comprising oncostatin m (OSM) antagonist derivatives and methods of use
TWI904261B (zh) 2020-10-19 2025-11-11 美商碩騰服務公司 犬及貓抑瘤素M受體β之抗體及其用途

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DD266710A3 (de) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・2・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
EP0368684B2 (en) 1988-11-11 2004-09-29 Medical Research Council Cloning immunoglobulin variable domain sequences.
FR2646437B1 (fr) 1989-04-28 1991-08-30 Transgene Sa Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant
US6291158B1 (en) 1989-05-16 2001-09-18 Scripps Research Institute Method for tapping the immunological repertoire
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
ES2196002T3 (es) 1991-07-25 2003-12-16 Idec Pharma Corp Anticuerpos recombinantes para terapia humana.
EP0605522B1 (en) 1991-09-23 1999-06-23 Medical Research Council Methods for the production of humanized antibodies
GB9122820D0 (en) 1991-10-28 1991-12-11 Wellcome Found Stabilised antibodies
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
GB9203459D0 (en) 1992-02-19 1992-04-08 Scotgen Ltd Antibodies with germ-line variable regions
CA2140280A1 (en) 1992-08-17 1994-03-03 Avi J. Ashkenazi Bispecific immunoadhesins
ATE183513T1 (de) 1993-06-03 1999-09-15 Therapeutic Antibodies Inc Herstellung von antikörperfragmenten
JP3622208B2 (ja) 1993-06-11 2005-02-23 東ソー株式会社 骨粗鬆症治療方法及び治療薬
US5429746A (en) 1994-02-22 1995-07-04 Smith Kline Beecham Corporation Antibody purification
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
GB9806530D0 (en) * 1998-03-26 1998-05-27 Glaxo Group Ltd Inflammatory mediator
ES2230848T3 (es) 1998-04-28 2005-05-01 Smithkline Beecham Corporation Anticuerpos monoclonales con inmunogenicidad reducida.
MXPA05000511A (es) 2001-07-12 2005-09-30 Jefferson Foote Anticuepros super humanizados.
GB0216648D0 (en) 2002-07-18 2002-08-28 Lonza Biologics Plc Method of expressing recombinant protein in CHO cells

Similar Documents

Publication Publication Date Title
JP2007530068A5 (https=)
RU2006134477A (ru) Иммуноглобулины
JP2024156852A (ja) 結合タンパク質及びその使用方法
CN109517065B (zh) Il-18结合分子
US20240353422A1 (en) Method for obtaining april-binding peptides, process for producing the peptides, april-binding peptides obtainable with said method/process and use of the april-binding peptides
US20140212423A1 (en) Blood-brain barrier penetrating dual specific binding proteins
JP6513657B2 (ja) Il−17a結合剤およびその用途
RU2010149746A (ru) Перекрестно-реактивные антитела анти-il-17a/il-17f и способы их применения
JP2021101720A5 (https=)
KR20180048712A (ko) Tl1a에 특이적으로 결합하는 항체
RU2011149334A (ru) Анти-il-17f антитела и способы их применения
EP2771362A1 (en) Immunobinders directed against tnf
JP2020521504A (ja) 抗cd40抗体、その抗原結合フラグメント、およびその医学的使用
CN109721656B (zh) 靶向rankl的治疗性抗体
CN113677701B (zh) 产生亲合结合多特异性抗体的方法
TW202334220A (zh) 人類腫瘤壞死因子α抗體
WO2013186630A2 (en) Humanized antibodies to ca215
GB2600273A (en) Antibody to leptin receptor
US20190225680A1 (en) Tenascin Epitope and Antibodies Thereto
US10584175B2 (en) FN14-binding proteins and uses thereof
CN114106163A (zh) SARS-CoV-2病毒中和抗体及其用途
US20260116963A1 (en) Anti-il-13 antibodies and methods of use thereof
AU2024319932A1 (en) Btn3a-binding protein and medical uses thereof
RU2779128C2 (ru) Антитело к cd40, его антигенсвязывающий фрагмент и его медицинское применение
CN120476139A (zh) 抗tslp抗体及其应用